Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 18, 2019

Perioperative Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs Fluorouracil or Capecitabine + Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or GE Junction Adenocarcinoma

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial
Lancet 2019 Apr 11;17(12)1697-1708, S-E Al-Batran, Nils Homann, C Pauligk, et al

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading